Skip to main content
Equibles
EDSA logo

EDSA · Edesa Biotech, Inc. · Metrics

Track EDSA — free

Use EDSA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research EDSA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.77 +0.01 (+0.36%) At close · Oct 23
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company’s ability to continue as a going concern is dependent on obtaining additional funding through financings, other strategic activities as well as via grants, to fund the development of its drug candidates. There can be no assurance that the Company will be successful in raising the necessary financing. These conditions indicate the existence of a material uncertainty that may cast substantial doubt about the Company’s ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$26.71M
Shares
9.64M
Volume · Oct 23 18.56K Avg daily vol (3M) 60.35K

EDSA metrics

70 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.77
Market cap
$26.71M

Price action

20 metrics
Price change (1W)
+7.8%
Price change (30D)
-24.1%
Price change (3M)
-47.2%
Price change (6M)
-61.8%
Price change (YTD)
+95.1%
Price change (1Y)
+3.0%
Trailing year
Price change (5Y)
—
52-week high
$18.28
52-week low
$0.80
Change from 52-week high
-84.8%
Change from 52-week low
+246.3%
Annualized volatility
195.9%
Annualized volatility (3M)
87.4%
Beta
-0.6
RSI (14D)
32.6
Price vs SMA 50
-31.8%
Price vs SMA 200
-50.8%
Avg volume (3M)
60,345
Relative volume
0.3
Average dollar volume
$270,820

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
9.64M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
3.0
reciprocal yield 33.0%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-52.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
31,485.3×
reciprocal yield 0.0%
EV / revenue historical average (5Y)
31,485.3×
reciprocal yield 0.0%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2021-02-16

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
$0
Operating profit (TTM)
−$14.63M
Net income (TTM)
−$14.10M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.00
Gross profit per diluted share (TTM)
$0.00
Operating profit per diluted share (TTM)
$-14.55
EBITDA per diluted share (TTM)
$-14.49
Net income per diluted share (TTM)
$-8.13
Operating cash flow per diluted share (TTM)
$-7.84
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$11.42
Stock compensation per diluted share (TTM)
$1.66
Book value per share
$1.74

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
-380.0%
Shares change YoY
+29.9%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-160.0%
Return on assets
-110.9%
Debt / equity
—
Current ratio
2.8
EBITDA (TTM)
−$14.53M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$10.30M
Latest balance sheet
Cash & equivalents
$10.30M
Total assets
$12.72M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$8.91M
Capital expenditures (TTM)
$0
R&D (TTM)
$9.08M
SG&A (TTM)
—
Stock compensation (TTM)
$1.84M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
33
13F filer change QoQ
+5
Institutional ownership
38.9%
Conviction holders (share of 13F filers)
3.0%
Crowding (high-turnover and private-fund holders)
38.7%
Private-fund adviser ownership
37.1%
Active holders' share change QoQ
+47.0%
Holder tenure
4.1
Price vs estimated holder cost
+65.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
1.4%

Short interest

3 metrics
Short interest
2.1%
Latest settlement · 4.8 days to cover
Days to cover
4.8d
Short-squeeze score
42 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1540159 CUSIP 27966L306 13F (30d) 2 filings 2 filers Visit website Investor relations